Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Biodesix, Inc. (BDSX : NSDQ)
 
 • Company Description   
Biodesix Inc. is a data-driven diagnostic solutions company. It offers blood-based tests across the lung cancer continuum of care. The company also offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as develops and commercializes companion diagnostics. Biodesix Inc. is based in Boulder, Colorado.

Number of Employees: 273

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.27 Daily Weekly Monthly
20 Day Moving Average: 1,685,019 shares
Shares Outstanding: 146.56 (millions)
Market Capitalization: $39.81 (millions)
Beta: 0.97
52 Week High: $2.04
52 Week Low: $0.17
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -3.62% -8.84%
12 Week -52.35% -60.03%
Year To Date -82.25% -83.37%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
919 WEST DILLON RD.
-
LOUISVILLE,CO 80027
USA		 ph: 303-417-0500
fax: -		 chris.brinzey@westwicke.com http://www.biodesix.com
 
 • General Corporate Information   
Officers
Scott Hutton - President; Chief Executive Officer
John Patience - Chairman and Director
Robin Harper Cowie - Chief Financial Officer; Secretary and Treasurer
Christopher C. Vazquez - Chief Accounting Officer
Jean Franchi - Director

Peer Information
Biodesix, Inc. (CHCR)
Biodesix, Inc. (ESRX)
Biodesix, Inc. (MYDP)
Biodesix, Inc. (COR)
Biodesix, Inc. (GBCS)
Biodesix, Inc. (LAXAF)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Medical Services
Sector: Medical
CUSIP: 09075X108
SIC: 8071
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/06/25
Share - Related Items
Shares Outstanding: 146.56
Most Recent Split Date: (:1)
Beta: 0.97
Market Capitalization: $39.81 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.06 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.25 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/06/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.60
Price/Cash Flow: -
Price / Sales: 0.53
EPS Growth
vs. Year Ago Period: 42.86%
vs. Previous Quarter: -33.33%
Sales Growth
vs. Year Ago Period: 21.19%
vs. Previous Quarter: -12.10%
ROE
06/30/25 - -
03/31/25 - -167.28
12/31/24 - -214.78
ROA
06/30/25 - -
03/31/25 - -39.96
12/31/24 - -42.36
Current Ratio
06/30/25 - -
03/31/25 - 2.22
12/31/24 - 2.76
Quick Ratio
06/30/25 - -
03/31/25 - 2.22
12/31/24 - 2.76
Operating Margin
06/30/25 - -
03/31/25 - -53.95
12/31/24 - -59.85
Net Margin
06/30/25 - -
03/31/25 - -54.28
12/31/24 - -60.19
Pre-Tax Margin
06/30/25 - -
03/31/25 - -54.28
12/31/24 - -60.19
Book Value
06/30/25 - -
03/31/25 - 0.08
12/31/24 - 0.14
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 3.32
12/31/24 - 1.74
Debt-to-Capital
06/30/25 - -
03/31/25 - 76.84
12/31/24 - 63.56
 

Powered by Zacks Investment Research ©